Swiss pharmaceutical company Roche has significantly expanded its artificial intelligence (AI) infrastructure by purchasing thousands of advanced chips from Nvidia, aiming to accelerate drug discovery and improve the efficiency of its research and development operations.
The company has installed more than 2,000 high-performance graphics processing units (GPUs) across its research centres in the United States and Europe. These chips provide the computing power required to process vast amounts of biomedical data and run complex simulations used in modern drug development.
By expanding its AI computing capacity, Roche plans to speed up several stages of the pharmaceutical research process. Scientists will be able to analyse large clinical and biological datasets faster, design potential drug molecules more efficiently and simulate how treatments may work in the human body before they enter clinical trials.
The investment is part of Roche’s ongoing collaboration with Nvidia to integrate advanced AI tools into pharmaceutical research. The enhanced computing platform will support the development of AI models capable of identifying promising drug targets, predicting outcomes in clinical trials and improving diagnostics.
According to Roche executives, faster computing power is becoming essential in the pharmaceutical industry as companies attempt to shorten the long timelines associated with drug development. Developing a new medicine can often take more than a decade and cost billions of dollars, making technologies that increase research productivity highly valuable.
With the latest deployment, Roche has built one of the largest AI-focused computing infrastructures in the pharmaceutical sector. The company expects the expanded system to help researchers run complex analyses in hours instead of days, allowing teams to test more hypotheses and accelerate scientific discovery.
Also Read: NCLT clears Adani Enterprises plan to acquire Jaiprakash Associates